CBOE and Canary Capital report, but no SEC confirmation.Market awaits clarity on filing status.Market has not reacted significantly to ETF news.
Canary Capital’s quest to introduce the first collateralized INJ ETF in the U.S. faces uncertainty, as official filings or confirmations remain absent from Cboe and SEC records.
The absence of concrete filings raises questions about market readiness, adherence to regulatory scrutiny, and potential impacts on INJ token value and broader crypto ETF market trends.
Canary Capital’s filing of an S-1 for the proposed ETF emerged on July 17 and was intended to provide exposure to Injective (INJ) with staking opportunities. While Canary Capital highlighted its intention to deliver staking rewards to shareholders, no public SEC or Cboe confirmation affirms the application for the INJ ETF. Stakeholders face ongoing uncertainty as the application lacks verification in public records. There is no evidence of a Cboe submission formally posted by the SEC or verified through Cboe’s listings. In the absence of SEC or exchange confirmation, industry participants have not initiated major reactions. “We filed the S‑1 for the Canary Staked INJ ETF to provide regulated exposure to Injective with staking rewards passed through to shareholders, subject to SEC approval.” – Steven McClurg, Founder & CEO, Canary Capital
According to CoinMarketCap, Injective (INJ) is currently priced at $14.06, with a market cap of formatNumber(1405386098, 2). Trading volume over the last 24 hours saw a change of 20.59%, and the circulating supply records at 99,970,935 INJ. Price variations include a one-day dip of 1.65% but a week’s growth of 4.19%. Recent statistical analysis by Coincu suggests a delay in Cboe’s application could disrupt short-term trading strategies linked to INJ, as investors weight the impact on token-derived instruments.
In the absence of SEC or exchange confirmation, industry participants have not initiated major reactions.
Did you know? Since June 2021, no US-listed ETF proposal involved staking underlying assets at scale, highlighting this ETF’s unique challenges in regulatory approval.
According to CoinMarketCap, Injective (INJ) is currently priced at $14.06, with a market cap of formatNumber(1405386098, 2). Trading volume over the last 24 hours saw a change of 20.59%, and the circulating supply records at 99,970,935 INJ.
Recent statistical analysis by Coincu suggests a delay in Cboe’s application could disrupt short-term trading strategies linked to INJ, as investors weight the impact on token-derived instruments.
